EC Number   |
Protein Variants |
Reference |
|---|
   2.7.11.13 | D116A |
site-directed mutagenesis, isozyme PKCgamma domain C1B mutant shows unaltered activity |
662165 |
| 2.7.11.13 | D55A |
site-directed mutagenesis, isozyme PKCalpha and PKCgamma mutants show unaltered activity and ligand binding, isozyme PKCalpha shows enhanced activation by phospholipids |
662165 |
| 2.7.11.13 | DELTA621-622 |
deletion of two residues in the AGC linker that passes through the cleft of the C1B domain (DELTA621622) results in a 2fold decrease in the concentration of phorbol 12-myristate 13-acetate required to mediate half-maximal translocation |
724707 |
| 2.7.11.13 | F629D |
within the NFD helix, mutant F629D and mutant F633D lead to 2- to 5fold decrease in EC50 for phorbol 12-myristate 13-acetate induced translocation |
724707 |
| 2.7.11.13 | F633D |
within the NFD helix, mutant F629D and mutant F633D lead to 2- to 5fold decrease in EC50 for phorbol 12-myristate 13-acetate induced translocation |
724707 |
| 2.7.11.13 | K368A |
a dominant-negative mutant of PKCalpha |
673352 |
| 2.7.11.13 | K368D |
site-directed mutagenesis of isozyme PKCalpha ATP-binding site, a dominant-negative mutant |
672423 |
| 2.7.11.13 | K371R |
site-directed mutagenesis, inactive isozyme PKCbetaII mutant |
662235 |
| 2.7.11.13 | L125D |
mutation of Leu125 in the C1B domain, which is part of the C1B clamp interface, increases EC50 for phorbol 12-myristate 13-acetate induced translocation more than 10fold |
724707 |
| 2.7.11.13 | L255G |
mutated activator-binding site: mutation reduces affinity for both phorbol ester and diacylglycerol. Mutation causes significantly reduced membrane translocation by phorbol ester treatment |
724241 |
